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INTRODUCTION 
Status epilepticus is defined as a seizure lasting more than 30 minutes 
or recurrent seizures for more than 30 minutes during which the patient does 
not regain consciousness.[1] 
Status Epilepticus is a common medical neurological emergency 
associated with high morbidity; if not, associated with mortality [2]  
     As an initial treatment, potent gamma-butyric agonists such as 
benzodiazepines will be administered to stop the child’s convulsions. 
Lorazepam and Diazepam are commonly used as first line drugs. They are 
short acting drugs which produce immediate effects. A long acting 
anticonvulsant drug is necessary to prevent recurrent convulsions. Phenytoin 
and Phenobarbitone were frequently used to treat status epilepticus in children. 
After the development of fosphenytoin, it is recommended as a second line 
therapy but both phenytoin and fosphenytoin can cause blood pressure 
reduction and arrhythmias. 
Levetiracetam is another antiepileptic effective against status 
epilepticus, which is associated with lower incidence of adverse effects. [3] 
The purpose of this study was to determine whether intravenous 
Fosphenytoin or intravenous Levetiracetam is a better second line 
anticonvulsant based on efficacy and safety for treatment of convulsive Status 
Epilepticus in pediatric population. 
 
2 
 
REVIEW OF LITERATURE 
 
DEFINITION OF SEIZURE : 
A seizure is defined as transient occurrence of signs and symptoms due 
to abnormal excessive synchronous neuronal activity in brain.[4] 
 
STATUS EPILEPTICUS 
CLASSICAL DEFINITION: 
           Status epilepticus is classically defined as “condition characterized by 
an epileptic seizure that is sufficiently prolonged or repeated at sufficiently 
brief interval so as to produce an enduring and unvarying epileptic 
condition”.[5] 
 
ILAE DEFINITION 
           Status epilepticus is a condition resulting either from failure of the 
pathway  responsible for termination of seizure or from the initiation , which 
lead to  prolonged seizure (after time point t1 ). It is a condition, which may 
have long  term consequences (after time point t2) including neuronal injury , 
alteration of  neuronal network and neuronal injury , depending on duration 
and type of  seizure[6]. 
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TABLE 1 - TWO OPERATIONAL DIMENSIONS IN STATUS 
EPILEPTICUS [6] 
 
(t1 - time point 1; t2 - time point 2) 
 
INDIAN ACADEMY OF PEDIATRICS[1] 
 
Status Epilepticus (SE): A seizure lasting more than 30 minutes or recurrent 
seizures for more than 30 minutes during which the patient does not regain 
consciousness.  
Operational Definition*: Generalized, convulsive status epilepticus in adults 
and older children (>5 years old) refers to >5 min of (i) continuous seizures or 
(ii) two or more discrete seizures between which there is incomplete recovery 
of consciousness.  
S.No TIME POINT 
OPERATIONAL 
DIMENSION 
TIME IN 
CONVULSIVE 
SE 
TIME IN 
FOCAL SE 
1  After  t1 
*Seizures should be 
regarded as “ continuous 
seizure activity” 
*It indicates when 
treatment should be 
initiated 
5 min 30 min 
2  After  t2 
 
*It indicates when long 
term consequences may 
appear. 
10 min >60 min 
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Refractory SE: Seizures persist despite the administration of two appropriate 
anticonvulsants at acceptable doses, with a minimum duration of status of 60 
minutes by history  or on observation. 
Super-Refractory SE: SE that continues 24 hours or more after the onset of 
anesthesia, including those cases in which the status epilepticus recurs on the 
reduction or withdrawal of anesthesia. 
Operational definition is used for the purpose of initiating treatment.[1] 
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BURDEN  
 The annual incidence of status epilepticus ranges from 9.9-41 per 
10000 / year with peaks in pediatric population and elderly[7] 
           The burden of disease, estimated using DALY, accounts for 1% of the  
total burden of disease in the world. The annual economic burden of seizure 
disorder in our country is 0.5% of GNP [8].  
Incidence of status epilepticus is more in poor population. Its 
prevalence is higher in rural (1.9%) compared with the urban 
population(0.6%).[8] In children the etiology is usually acute central nervous 
system infection . 
 According to an UK study, majority of cases of status epilepticus occur 
in children who are previously neurologically normal. Around quarter of the 
cases of status epilepticus are due to prolonged febrile seizures  and  17% of 
them are acutely symptomatic [9].  
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RISK FACTORS FOR REFRACTORINESS [10]: 
• Non convulsive status epilepticus 
• Hyperglycemia at presentation 
• Low Glasgow coma scale 
• Focal motor seizures at onset. 
 
CLASSIFICATION  
BASED ON SEMIOLOGY [6] 
TABLE 2 – CLASSIFICATION OF SEIZURES BASED ON 
SEMIOLOGY 
 
 MOTOR ACTIVITY DEGREE OF IMPAIRED CONSIOUSNESS 
A With prominent motor activity 
A1 -   Tonic clonic SE 
A2 -    Myoclonic SE 
A3 -    Focal motor SE 
B Without prominent motor 
activity 
B1 -    NCSE with coma 
B2 -    NCSE without coma 
 
 
BASED ON EEG: 
 Various factors to be scored are location, name of pattern, morphology, time 
related  features,  modulation and effect of intervention on EEG.[6] 
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BASED ON ETIOLOGY [6]: 
TABLE 3 CLASSIFICATION OF SEIZURES BASED ON ETIOLOGY 
 
1 Acutely symptomatic  Seizures due to head injury, 
hypoxemia, hypoglycemia, acute 
infection, electrolyte imbalance, drug 
withdrawal or intoxication 
2 Remote symptomatic Seizures secondary to static illness 
(remote cerebral insult in neonatal 
period) 
3 Progressive encephalopathy Status epilepticus  in children with 
progressive CNS disorder ( lipid 
storage disease, mitochondrial 
disorder, Rasmussen encephalitis ) 
4 Cryptogenic status epilepticus  Without any identifiable etiology 
 
FEBRILE STATUS EPILEPTICUS 
• It is a separate entity. 
• It is the most common type of SE in children.[4] 
• Febrile illness is the only provocation for status epilepticus. It 
should be  considered after excluding direct CNS infection. 
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     BASED ON AGE [6]: 
• Neonatal (< 30 days) 
• Infancy  
• Childhood (2- 12 years) 
• Adolescence 
• Elderly (above 60 years) 
•  
PATHOPHYSIOLOGY : 
TABLE 4 – NEUROTRANSMITTERS IN SE [4] 
  
Sustained Seizures are due to reduced inhibition and increased excitation 
based on neuro- chemical levels. 
1 Excitatory neurotransmitter  
Glutamate is the most common one and 
NMDA (N-Methyl D Aspartate ) 
receptor is involved  
2 Inhibitory neurotransmitter 
GABA (Gamma Amino Butyric Acid) is 
the common inhibitory neurotransmitter. 
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FIGURE 1 – PATHOPHYSIOLOGY OF STATUS EPILEPTICUS 
 
 
Status epilepticus results in both neuronal necrosis and apoptosis. Apoptosis  
occurs as a result of increase in pro-apoptotic factors( like apoptosis inducing 
factor, BAX protein and ceramide) and intracellular calcium.[4] 
 
PGE2 can raise glutamate release and lower potassium current which  
eventually lead to increased excitability.[4] 
 
Sustained seizures reduce GABA inhibition progressively. At receptor level  
 GABAnergic pathway fails and seizures become resistant to 
pharmacotherapy[4] 
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OTHER MALADAPTIVE CHANGES: 
• Depletion of inhibitory neuropeptides like galanin , somatostatins  and  
neuropeptide in hippocampus.[11] 
• Reduction of chloride gradient across neuronal membrane[11] 
• Increase in expression of substance P and tachykinins[11] 
 
 
PHYSIOLOGICAL CHANGES IN  STATUS EPILEPTICUS        
    Generalized convulsive status epilepticus 
 
 
            Catecholamine surge     Vigorous muscle activity      Marked acidosis 
                                                      & Central sympathetic drive 
 
 
                          Tachycardia             Hyperthermia           Both respiratory  
                        Tachypnoea                                           & metabolic component 
                    Cardiac arrhythmia 
                                                Associated with poor        Acidosis resolves with  
                                                 neurologic outcome         control of seizure 
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ETIOLOGY [4]: 
 New onset epilepsy of any type 
 Febrile convulsion (6 months – 5 years)  
 Hypoxic ischemic encephalopathy 
 Infections (CNS infections-Encephalitis, Meningitis) 
 Head trauma 
 Metabolic causes (Hypoglycemia, Hyponatremia, 
                                 Hypomagnesemia, Hypocalcemia) 
 Neurodegenerative disorders 
 Neurocutaneous syndrome  
 Toxins(camphor, heavy metals, organophosphates) 
 Medication changes Non compliance (anti-epileptic 
drugs) Inadequate dosage. 
 Ischemic Stroke (Arterial or Venous) 
 Inborn errors of metabolism – Storage disorders 
 Intracranial hemorrhage 
 Systemic conditions (Hypertensive or Renal or Hepatic 
encephalopathy) 
 Brain Tumors 
 Acute symptomatic status epilepticus is the most common category in 
pediatric  population. 
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PROGNOSIS: 
Factors that affect prognosis in children with Status Epilepticus are,  
  1. Type of seizure 
  2. Duration of seizure  
  3. Etiology of seizure 
                      4. Age of the child 
 
Type of seizure: 
                      Focal and NCSE are associated with refractory status 
epilepticus[10]                     
 
Duration of seizure: 
Prolonged seizures lead to hypoglycemia, hypercarbia, hypoxia and 
marked acidosis which eventually leads to neuronal destruction[12] 
 
Etiology of seizure: 
According to Nelgian et al, mortality is low in children classified as 
idiopathic and febrile Status Epilepticus [13].  Most death occurs in children 
with acute symptomatic and remote symptomatic causes. [14] 
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Age of the child: 
TABLE 5 – AGE OF CHILD IN RELATION TO PROGNOSIS OF SE [15] 
S. No. Age Sequelae rate 
1 <1 year 29% 
2 1-3 years 11% 
3 >3 years 6% 
                            
COMPLICATIONS OF STATUS EPILEPTICUS: 
1. Hypoxemia 
  It occurs due to impaired ventilation, excessive tracheobronchial  
secretion and increased oxygen consumption.  
 Severe hypoxia and acidosis leads to impaired myocardial 
contractibility,  reduced stroke volume and hypotension.  
2. Acidosis (both respiratory and metabolic) 
3.Glucose alterations 
 
TABLE 6 – ALTERATION OF BLOOD GLUCOSE IN SE 
During early phase of 
status epilepticus 
Massive Catecholamine release 
&Sympathetic surge Hyperglycemia 
Prolonged status 
epilepticus 
Increased metabolic demand 
 
Hypoglycemia 
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4. Blood pressure disturbances 
 BP and Heart rate rise at early phase due to massive sympathetic surge 
and catecholamine release, but prolonged seizures lead to decline in blood 
Pressure. 
 
5.  Intra Cranial Pressure 
  Increase in intra cranial pressure further interferes with cerebral 
oxygen and substrate supply. This results in cerebral edema.  
 Other factors that contribute to increased intra cranial pressure are 
hypoxemia, hypercarbia and metabolic acidosis with compensatory 
vasodilatation and increased blood flow to cerebrum[16] 
 
6.Other effects 
     Hyperpyrexia [17] 
     Hyperkalemia (due to rhabdomyolysis)  
     Acute renal failure due to myoglobinuria and hypotension  
     Apnea [18] 
                         Aspiration pneumonia 
     Neurogenic pulmonary edema [18] 
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7.Morbidity  
Neurologic sequelae (Focal motor deficit [4], Intellectual deficit, 
Behavioral disturbances Epilepsy) 
 
8. Mortality (3% - 9%) 
 
DIAGNOSIS : 
 
1. History and clinical examination using systematically designed 
proforma. 
2.  Investigations in child with status epilepticus [1] 
First line investigation 
Without previous seizure history 
 1. Random blood sugar 
 2. Serum sodium (especially < 6 months) 
 3. Calcium (if < 2 years) 
With previous seizure history 
1. AED level 
If febrile 
 1. Complete blood count 
 Lumbar puncture 
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Refractory status epilepticus 
 1. Video EEG recording 
Second line investigation 
 1. EEG 
 2. Neuro imaging (MRI is most sensitive) 
 
Special tests 
1. If history suggestive of metabolic disorder, consider metabolic and 
genetic  testing. 
2. Workup for autoimmune encephalitis. 
3. Urine toxicology. (if clinical suspicion) 
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TREATMENT PROTOCOL 
FIGURE 2 – TREATMENT OF CONVULSIVE  STATUS 
EPILEPTICUS IN CHILDREN AND ADULTS 
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GENERAL MANAGEMENT OF ACUTE SEIZURES: 
STABILISING THE CHILD 
In the convulsing child, initial supportive, therapeutic and diagnostic measures 
need to be conducted simultaneously. The goal of the therapy is to stop 
clinical end electrical seizure activity by promptly giving appropriate drugs, in 
adequate doses, with attention to the possibility of complicating apnea, 
hypoventilation and other metabolic abnormalities.  
When stabilizing the child, the main priority in management is preserving vital 
function. That is, protecting the airway, maintaining breathing, supporting the 
circulation, and correcting the metabolic derangements. 
 
 PHARMACOTHERAPY 
1. BENZODIAZEPINES :  
 
They are first line anticonvulsants for the treatment of SE in children. 
In our study 
Midazolam was the benzodiazepine of choice. 
Advantages of Midazolam: 
             Increased water solubility 
             Shorter duration of action & 
             Better local tolerance when injected intravenously [19] 
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Route of administration : 
• Buccal 
• Intranasal  
• Intravenous & Intramuscular.[19] 
 
Dosage: 
 0.15 -0.2 mg/kg (max upto 5 mg) -- may repeat in 5-10 min[1] 
 
2.LEVETIRACETAM 
Chemical structure  
 It is the S-enantiomer of alpha-ethyl-2-oxo-1-pyrrolidine acetamide, 
with a molecular weight of 170.21 and the chemical formula C8H14N2O2.[20] 
 
FIGURE 3 – CHEMICAL STRUCTURE OF LEVETIRACETAM 
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Mechanism of action 
 The proposed mechanism of levetiracetam action related to its binding 
to synaptic vesicle protein (SV2A) is a predominant isoform of the three 
known SV2  proteins [20] 
Binding of the levetiracetam to SVA2 results in synaptic release of 
glutamate and GABA [20] 
Pharmacokinetics: 
Volume of distribution 
                      0.5 to 0.7 liter per kg  
Tmax : 
                                2 - 46 months   1.4 hr 
            4 - 12 years  0.5 hr  
Half-life : 
                       2 – 46 months   5.3 hrs 
             4 – 12 years  4.9 hrs  
Clearance : 
                                2 – 46 months   1.4 ml/min/kg 
            4 – 12 years  1.12 ml/min/kg  
Protein binding : 
 Protein binding of levetiracetam is insignifigant (<10 %). 
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Metabolism : 
 Levetiracetam biotransformation pathway is not cytochrome p450 
dependent.  
It has low potential for significant pharmacokinetic interaction 
because it’s major metabolic pathway is hydrolysis and it undergoes negligible 
oxidative metabolism in liver. Levetiracetam does not induce or inhibit drug 
metabolizing enzymes[20] 
Excretion : 
  Main route of excretion is by renal route either in administered form 
(66%) or as  carbolic acid metabolite (pharmacologically inactive form) as a 
result of amide functional group hydrolysis.[20] 
Dosage : 
Intravenous Levetiracetam 
Acceptable dose ranges from 20- 60 mg / kg can be used for 
convulsive  status epilepticus with transient side  effects even at upper limits  
of dose range. 
Reconstitution fluids : 
     The suitable diluents are 0.9 % sodium chloride, 5 % dextrose  & 
Ringer lactate. 
Rate of infusion : 
               Rate of infusion is 5 mg / kg/min [1] 
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Storage : 
  It is stored between 20 – 25° C. 
Adverse effects : 
  According to Oluwaseun Egunsola [21], the most common 
adverse event  that warrants discontinuation were behavioral problems 
(10.9%) and somnolence (8.7%). 
 
TABLE 7 – ADVERSE EFFECTS OF LEVETIRACETAM. 
S.NO ADVERSE EVENT PERCENTAGE 
1. Behavioral problems  
 
 
More frequent[22] 2 Fatigue 
3 Irritability   
4 Unsteadiness  
5. Somnolence 
6 Nervousness   
 
 
Less frequent[22] 4 Anorexia 
5 Anxiety 
6 Rhinitis  
7 Abnormal hepatic function  
 
Rare  8 Dermatological problems 
9 Bone marrow suppression 
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3. FOSPHENYTOIN  
  Fosphenytoin sodium is a phosphate ester, prodrug of 
phenytoin[23]. It was developed as replacement for phenytoin sodium. 
Chemistry : 
  Chemical formula : C16H15N2O6P 
  Molar mass : 362.274 g/mol 
 
FIGURE 4 - CHEMICAL STRUCTURE OF FOSPHENYTOIN 
 
 
Mechanism of action : 
  Fosphenytion stabilizes neuronal membrane thereby prevents 
recurrent detonation of normal neuronal cells during depolarization shift 
which occurs in epileptic  patients and consists of synchronous and large 
depolarization over which action  potential is overlapped. This is brought by 
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prolonging the inactivated stage of voltage  sensitive sodium channel which 
governs the refractory period of neuron. This results in  inhibition of high 
frequency discharges with negligible effect on low frequency  discharges 
which allows sodium channels to recover even when their inactivation is  
continued. This effect of fosphenytoin has been noted at therapeutic 
concentration[23]. 
 Other effects like inhibition of glutamate response, facilitation of 
GABA response and reduction in calcium influx have been oted at toxic 
concentration[23] 
 
Pharmacokinetics 
 The conversion half life of fosphenytoin is nearly 15 minutes. The 
mechanism of conversion has not been established but phosphatases play a 
primary role. Each mole of fosphenytoin is converted to one mole of formate, 
phenytoin and  phosphate[24, 25] 
 
Absorption : 
 Fosphenytoin has a half-life of 15 minutes following intra venous 
infusion. Fosphenytoin is completely bioavailable follow intramuscular 
administration but peak  concentration occurs approximately after 30 
minutes.[24,25] 
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 Plasma fosphenytoin concentration following intramuscular 
administration  is more sustained but lower than those following intra venous 
infusion because of the  time required for fosphenytoin absorption from the 
site of injection.[24,25] 
 
Metabolism : 
 Bioavailability of various market preparation may differ. Hence it is 
adviced to use single brand. It is 95% - 99% protein bound (especially 
albumin). The percentage bound is lowered as total fosphenytoin 
concentration increases which is aresult of the fact that binding to plasma 
proteins is saturable. [23] 
Fosphenytoin takes the place of phenytoin in protein binding sites. 
Phenytoin is metabolized by glucuronide conjugation as well as by 
hydroxylation involving 2C19 and  CYP2C9 in liver[23,24,25] 
 
Volume of distribution : 
 Volume of distribution of fosphenytoin rises with dose and rate. 
Volume  of distribution is 4.3 – 10 liters .  
 
Excretion : 
  5% unchanged form is excreted in urine. [23] 
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Advantage of fosphenytoin over phenytoin : 
 Fosphenytoin is water soluble pro-drug of phenytoin that has been 
introduced to overcome the difficulties in intravenous phenytoin 
administration , which it has replaced for use in benzodiazepine-resistant 
status epilepticus. 
          Its advantages over phenytoin include more rapid intravenous infusion 
and lower potential for cardiac and local tissue toxicity.  Fosphenytoin can be 
infused with both glucose and saline, but phenytoin cannot be administered in 
a  drip of dextrose solution (because it results in precipitation)[23] 
Loading dose : 
 Loading dose for pediatric status epilepticus is 15mg PE /kg to 20mg 
PE/kg[1]. In the body fosphenytoin is rapidly changed to phenytoin sodium ; 
it’s doses are expressed in PE  (phenytoin equivalents) [24,25] 
 Because of risk of hypotension, fosphenytoin should not be infused at a  
rate of more than 150 mg PE/min in children. Continuous monitoring of 
respiratory function, electrocardiogram and BP is mandatory[23]. 
Rate of infusion : 
Rate of infusion is 2 – 3 mg PE/kg/min [1] 
Compatible fluid : 
  5% dextrose and 0.9 % sodium chloride. 
  Concentration required is 1.5 – 25 mg PE/ml [1] 
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Adverse effects : 
 Side effects of fosphenytoin are similar to phenytoin and includes 
cardiac arrhythmias, hypotension, CNS adverse effects(ataxia ,dizziness, 
somnolence, nystagmus, diplopia)[23] 
 
 Intra venous injections result in local vascular injury(damage to 
intima). This eventually leads to thrombosis of vein. Hence edema and 
discoloration of injected limb occurs. Extravasation of solution results in 
tissue necrosis[23] 
 
 Fall in BP and cardiac arrhythmias occur only on intra venous 
injections. 
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                 Kensuke Nakamura et al concluded that levetiracetam and 
fosphenytoin are equally efficacious in preventing recurrent seizures after the 
termination of SE by benzodiapezines. Further adverse events were lower and 
tolerable in LEV group.[26] 
                   Vincent Alvarez et al did a retrospective comparative study on 
phenytoin, levetiracetam and valproate as a second line status epilepticus 
treatment in adults. In this study, phenytoin failed to control SE in 41.4% 
patients and LEV in 48.3%. (p value is statistically in- significant)[27] 
                    Chakravarthi S et al studied the effectiveness of LEV and FPHT 
in adults with regard to primary and secondary outcomes. In their study, 
phenytoin achieved control of seizures in 68.2% compared to 59.1% in LEV 
and both the groups showed comparable results with respect to recurrence of 
seizures, the need of ventilator support and death. They concluded that LEV 
may be an attractive and effective alternative to phenytoin. [28] 
                    In the study by Manjari Tripathi et al, hypotension, respiratory 
depression, need of intubation, ICU care were not observed when status 
epilepticus was terminated with intravenous loading dose of levetiracetam.[29] 
                   Jaclyn O Connor et al concluded in their study, Levetiracetam is as 
safe  and effective as phenytoin for the treatment of status epilepticus with 
lower incidence of  adverse events.[3] 
              In a study by Knake et al, levetiractam terminated seizure activity in 
all patients and is not associated with any serious adverse events. [30] 
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              Ted Lee et al did a retrospective study on use of LEV in management 
of toxic seizures and concluded that LEV used as a second line anti- epileptic 
terminated drug induced seizures and prevented seizure recurrence without 
obvious adverse effects. [31] 
   According to Zeid Yasiry et al, the efficacy of phenytoin (50.2%) was 
found to be lower when compared to levetiracetam (68.5%) [32]. 
         In a study by Bernherds R Ogutu et al on the pharmacokinetics and  
clinical effects of phenytoin and FPHT in children with severefalciparum 
malaria and SE, they found that i.v or i.m fosphenytoin offers a convinent 
alternative to i.v phenytoin. [25] 
            According to Ilo E Leppik et al’s preclinical and clinical studies on  
phenytoin prodrug, they found that both i.v and i.m administrations of 
FPHT maintained stable levels of phenytoin. Both i.v and i.m FPHT were 
well tolerated by the patients as evidenced by the absence of serious 
adverse reactions. [33] 
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AIM AND OBJECTIVES 
 
 To compare the efficacy of I.V Fosphenytoin with I.V 
Levetiracetam in a pediatric population suffering from Status 
Epilepticus. 
 To compare the safety of Fosphenytoin with Levetiracetam in a 
pediatric population treated for Status Epilepticus. 
 To compare the incidence of recurrence between Fosphenytoin and 
Levetiracetam in a pediatric population with Status Epilepticus. 
 To compare the incidence of adverse reactions between 
Fosphenytoin and Levetiracetam when used to treat Status 
Epilepticus in a pediatric population. 
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MATERIALS AND METHODS 
 
 
STUDY DESIGN: 
      Prospective randomized control trial 
 
STUDY SETTING: 
     Govt. Rajah Mirasdar hospital. 
 
STUDY PERIOD: 
    January 2017 – July 2017 
 
STUDY POPULATION: 
     1 month – 12 years old children who presented to Pediatric Emergency 
department at Govt. Rajah Mirasdar Hospital in a convulsing state. 
 
INCLUSION CRITERIA: 
Children in age group of 1 month -12 years in whom seizure persisted 
after two doses of I.V Midazolam (0.15 mg/kg/dose). 
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EXCLUSION CRITERIA:  
 Child in shock. 
 Children who were previously on oral Phenytoin or oral 
Levetiracetam for seizure medications. 
 Pre-hospital treatment records were unavailable. 
 Administration of injectable AEDs (BZD, phenytoin, 
levetiracetam, sodium valproate) in the previous 24 hrs. 
 
SAMPLING TECHNIQUE: 
               Simple random sampling 
 
SAMPLE SIZE: 
              Sample size for our study was calculated using openepi.com , keeping 
the type 1 error (α) as 0.95 , power (β) as 0.8 , ratio of sample as 1 and mean 
difference (σ) as 0.5, the sample size required for each group is 25. Hence for 
two groups the sample required was 50. 
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METHODOLOGY OF COLLECTING DATA: 
A written consent obtained from parents / guardian during the time of 
enrolment. 
         The study sample was divided into two groups. Children treated with 
Fosphenytoin constitute Group I and those who received Levetiracetam 
constitute Group II. 
  
 HISTORY : 
• Current seizure activity : nature of onset , duration , any 
secondary generalization and the postictal sensorium in case the 
seizure has subsided. 
• Presence or absence of fever, any viral prodrome, ear discharge, 
neck pain, irritability or any other intercurrent illnesses. 
• Any prior history of seizures if present, specify if on 
medications, dosage and compliance. 
• Features of raised intracranial tension like headache / vomiting / 
posturing. 
• Intoxication or toxic exposure. 
• Other CNS abnormality (e.g. Ventricular-peritoneal shunt, prior 
CNS infection) 
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• Birth history (e.g. anoxic encephalopathy) 
• Developmental history (  by using Trivandrum developmental 
scale where all the milestones falling to the left of the vertical 
line should have been achieved by the child) 
• Family history of seizures 
 
EXAMINATION: 
• Vital signs: temperature, heart rate, respiratory rate and the 
blood pressure. 
• Look for features of respiratory distress, poor peripheral 
perfusion  and the hydration status  
• Note the type of seizure activity present. 
• Assess for features of raised intracranial pressure. 
• Also assess for possible etiology: features of meningitis, 
septicemia, trauma , neurocutaneous stigmata, toxin ingestion 
and any peculiar body odour. 
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LABORATORY STUDIES: 
            Obtain laboratory studies based on age and likely etiologies. 
• Blood glucose level 
• Electrolyte levels (sodium, potassium, calcium and if possible 
magnesium) 
• Arterial blood gas analysis 
• Toxicology screen (if suggestive history available) 
• Complete blood count 
• Renal function test 
• Liver function test 
• Cerebrospinal fluid examination 
• Neuroimaging and  Electroencephalography 
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STUDY FLOW-ALGORITHM: 
Airway, breathing, circulation 
 
Put the child in lateral position to avoid aspiration 
 
1st dose of I.V Midazolam 0.15mg/kg 
Wait 5 mins    if no response 
 
2nd dose I.V Midazolam 0.15 mg/kg 
Wait 5 mins     No response 
Randomization 
 
GROUP A                                                          GROUP B 
 
I.V Fosphenytoin 20mgPE/kg -10 mins              I.V Levetiracetam 30mg/kg -6 mins 
 
 
PRIMARY ASSESMENT            after 5 minutes              
                                                  No response   
             Inj. Phenobarbital 20 mg/kg I.V loading dose at 1mg/kg/min  
                   
Inj. Midazolam infusion as per guidelines 
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              Following drug administration, we compared both groups with the 
following parameters. 
 
Primary outcome 
Efficacy: 
a. Whether the episode of convulsive status epilepticus was  
terminated with FPHT and LEV. 
b. The need to use additional antiepileptic drugs to terminate the presenting 
convulsions 
c. Time taken from administration of drug in emergency department/PICU 
to termination of convulsion. 
 
Cessation of status: 
Defined as cessation of status and improving mental status following 
administration of drugs. 
Five minutes following the administration of study medication, assessment 
will be performed by the pediatric postgraduate. 
The patient will be examined for the following: 
1. Jerky movements 
2. Increased tone  
3. Level of consciousness 
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Continued seizure activity is defined as presence of either jerky 
movements or increased tone. If seizure activity is present, then the next 
anticonvulsant is to be infused as per the study protocol. 
The time at which convulsive activity has ceased (as defined above) is 
recorded. 
 
Secondary outcome: 
a. Whether convulsions recurred within 24 hours after termination of 
seizures following administration of FPHT and LEV. 
b. Seizure free duration in case of recurrence. 
c. Length of stay in PICU and hospital 
d. Occurrence of life threatening hypotension: within 60 minutes of 
administration of drugs. 
e. Need for intubation ( within 60 minutes following study drug infusion  
f. Incidence of adverse effects 
 (Hypotension: measured as greater than 20%reduction from baseline 
Respiratory depression: measured as greater than 20%reduction from baseline) 
           Children will be assessed daily while they remain in-patients to watch 
out for adverse events.  
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DATA ANALYSIS 
68 children between the age group of 1 month to 12 years who had 
Status Epilepticus and presented to Pediatric Emergency department at Govt. 
Rajah Mirasdar hospital, Thanjavur, during the study period as shown in the 
figure below. Those who had Status Epilepticus that persisted after 2 bolus of 
BZD I.V Midazolam (0.15 mg/kg/dose) were included in this study. Children 
with shock; on oral Phenytoin and Levetiracetam medications; and who were 
discharged against medical advice were excluded from the study.          
      68 babies 
 
 
Included 50 Children                                                             Excluded 
                                                                                           (18 Children)  
Group 1    Group 2 
Fosphenytoin                        Levetiracetam 
(n=25)             (n=25) 
 
                         
        Outcome analysis and result 
 
 
 
Excluded:  
• Children with shock;  
• On oral Phenytoin and 
Levetiracetam 
• Discharged against 
medical advice 
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AVAILABILITY, STORAGE AND DILUTION: 
• Available strength of Fosphenytoin is 75 mg PE/ ml (10 ml vial). 
(750 mg equivalent to 500mg of Phenytoin sodium). 
• Available strength of Levetiracetam is 100 mg/ml (5 ml vial).  
• Available strength of Midazolam is 1 mg/ml (5 ml vial). 
STORAGE: 
• Levetiracetam: It is stored at 25oC (77oF). 
• Fosphenytoin: It is stored under refrigeration at 2-8 oC. Product 
has to be discarded if kept at room temperature for more than 48 
hours, after reconstitution. 
• Midazolam: It is stored below 25oC. 
DILUTION: 
Commonly used diluent in our study was 0.9% sodium chloride 
solution for Midazolam, Levetiracetam and Fosphenytoin. 
INFUSION: 
Levetiracetam: 
• Concentration:  Required dosage + 100 ml compatible fluid. 
• Rate of infusion:  5 mg/kg/min. 
Fosphenytoin: 
• Concentration:  1.5 – 25 mg PE/ml. 
• Rate of infusion: 2 mg PE/kg/min. 
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STATISTICAL ANALYSIS: 
Comparisons of various domains of both groups were analyzed using: 
A. Mann-Whitney U test, 
B. Fisher’s Exact test, 
C. Unpaired ‘t’ test 
Inference of ‘P’ value is tabulated below: 
TABLE 8 – ‘P’ VALUE AND ITS SIGNIFICANCE 
S.NO. ‘P’  VALUE INTERPRETATION 
1 Less than or equal to 0.01 Highly significant 
2 Less than or equal to 0.05 Significant 
3 More than 0.05 Not Significant 
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RESULTS AND ANALYSIS 
 
BASELINE CHARACTERISTICS OF BOTH STUDY GROUP: 
1) COMPARISON OF AGE IN BOTH STUDY GROUP: 
 
TABLE 9 - COMPARISON OF CASE DISTRIBUTION BASED ON 
AGE IN FOSPHENYTOIN AND LEVETIRACETAM GROUP 
S. 
No. Parameter 
Group I 
(Fosphenytoin) 
(n=25) 
Group II 
(Levetiracetam) 
(n=25) 
‘p’ value Statistical Test 
 
1 
 
Age(in 
years) 
 
3.34 ± 3.6 
 
2.28 ± 2.19 
 
0.657(NS) 
Mann-
Whitney 
U test 
 
            Data are expressed as mean ± SD. P value less than 0.05 is considered 
as  significant and Mann Whitney U test was used to test the significance. 
 
Mean age in Fosphenytoin group was 3.34 ± 3.6 years whereas in 
Levetiracetam group, it was 2.28 ± 2.19 years which was not statistically 
significant (‘p’= 0.657). 
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FIGURE 5 - COMPARISON OF CASE DISTRIBUTION BASED ON AGE 
IN FOSPHENYTOIN AND LEVETIRACETAM GROUP 
 
 
*Data are expressed as mean ± SD. 
*The height of the bar in the vertical bar diagram represents the 
mean. 
*The error bar represents the standard deviation. 
*The total number of sample in each group was 25. 
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2) COMPARISON OF DISTRIBUTION OF GENDER IN FPHT & 
LEV GROUP: 
 
TABLE 10 - COMPARISON OF CASE DISTRIBUTION BASED ON 
GENDER IN FOSPHENYTOIN AND LEVETIRACETAM GROUP 
 
S. 
No. 
Parameter 
(sex) 
Group I 
(fosphenytoin) 
(n=25) 
Group II 
(levetiracetam) 
(n=25) 
‘p’ 
value 
Statistical 
Test 
1 Male 64%(16) 72%(18) 
0.762 
(NS) 
Fisher’s 
Exact test 
2 Female 36%(9) 28%(7) 
 
 
 
       Data are expressed as percentages. ‘p’ value less than 0.05 is considered 
as     significant and Fisher’s Exact test was used to test the significance. 
• 34 male children (68%) and 16 female children (32%) with Status 
Epilepticus were enrolled in this study.  
• Among the male children, 16 of them were included in 
Fosphenytoin group and remaining in Levetiracetam group. 
• Of the female children, 9 of them received Fosphenytoin and 
remaining received Levetiracetam.  
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FIGURE 6 – COMPARISON OF CASE DISTRIBUTION BASED ON 
GENDER IN FOSPHENYTOIN AND LEVETIRACETAM GROUP 
 
 
 
*Data are expressed as absolute numbers. 
*The Length of the bar in vertical bar diagram represents 
number of subjects (n). 
*The total number of sample in each group is 25. 
 
 
 
Male Female
FPHT 64 36
LEV 72 28
0
10
20
30
40
50
60
70
80
P
e
rc
e
n
ta
g
e
46 
 
3) COMPARISON OF WEIGHT OF THE CHILDREN BETWEEN 
TWO GROUPS: 
 
TABLE 11.COMPARISON OF CASE DISTRIBUTION BASED ON 
WEIGHT IN FOSPHENYTOIN AND LEVETIRACETAM GROUP  
 
S. 
No. Parameter 
Group I 
(Fosphenytoin) 
(n=25) 
Group II 
(Levetiracetam) 
(n=25) 
‘P’ 
Value 
Statistical 
Test 
1 Weight (in kg) 11.86 ± 8.9 10.42 ± 5.9 
0.95 
(NS) 
Mann-
Whitney 
U test 
 
               Data are expressed as mean ±SD. ‘p’ value less than 0.05 is 
considered as significant and Mann Whitney U test was used to test the 
significance. 
 
 In this study mean weight of children enrolled in Fosphenytoin group 
was 11.86 ± 8.9 kg whereas in Levetiracetam group it was 10.42 ± 5.90 kg 
which was not statistically significant (‘p’=0.95) 
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FIGURE 7 – COMPARISON OF CASE DISTRIBUTION BASED ON 
WEIGHT IN FOSPHENYTOIN AND LEVETIRACETAM GROUP 
 
 
 
*Data are expressed as mean ± SD. 
*The height of the bar in the vertical bar diagram represents the 
mean. 
*The error bar represents the standard deviation. 
 
Hence this study is a randomized control using age, gender and weight 
specific matching. 
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4) COMPARISON OF DEVELOPMENTAL STATUS: 
TABLE 12 - COMPARISON OF CASE DISTRIBUTION BASED ON 
DEVELOPMENTAL STATUS IN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
 
S.no Parameter Development 
Group I 
(Fosphenytoin) 
(n=25) 
Group II 
(Levetiracetam) 
(n=25) 
‘P’ 
Value 
Statistical 
Test 
1 Abnormal 32%(8) 28%(7) 
0.999 
(NS) 
Fisher’s 
Exact test 
2 Normal 68%(17) 72%(18) 
 
               Data are expressed as percentages. ’p’ value less than 0.05 is 
considered as significant and Fisher’s Exact test was used to test the 
significance. 
 Among the 50 children, 30% (15) of them were developmentally 
abnormal. 
Of whom, eight were treated with Fosphenytoin and seven with 
Levetiracetam. 
           However ‘P’ value was found to be statistically insignificant (0.999). 
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FIGURE 8 COMPARISON OF CASE DISTRIBUTION BASED ON 
DEVELOPMENTAL STATUS IN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
 
 
*Data are expressed as absolute numbers. 
*The Length of the bar in the vertical bar diagram represents 
number of subjects (n). 
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5) COMPARISON OF PREVIOUS HISTORY OF SEIZURES: 
 
TABLE 13 - COMPARISON OF CASE DISTRIBUTION BASED ON 
PREVIOUS SEIZURE HISTORY IN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
 
S. 
No. 
Parameter 
(Previous 
seizure) 
 
Group I 
(Fosphenytoin) 
(n=25) 
Group II 
(Levetiracetam) 
(n=25) 
‘P’ 
Value 
Statistical 
Test 
1 Yes 36%(9) 28%(7) 
0.762 
(NS) 
Fisher’s 
Exact test 
2 No 64%(16) 72%(18) 
 
                   Data are expressed as percentage. ‘p’ value less than 0.05 is 
considered as significant and Fisher’s Exact test was used to test the 
significance. 
 
          Among the 50 children, 16 children had a previous history of seizures. 
Among those, 9 of them were treated with Fosphenytoin and 7 with 
Levetiracetam. The ‘p’ value was not significant. 
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FIGURE 9 – COMPARISON OF CASE DISTRIBUTION BASED ON 
PREVIOUS SEIZURE HISTORY IN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
 
 
*Data are expressed as absolute numbers. 
*The Length of the bar in the vertical bar diagram represents 
number of subjects (n). 
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6) COMPARISON OF FREQUENCY OF PREVIOUS ANTI-
EPILEPTIC DRUG INTAKE IN BOTH GROUPS: 
 
TABLE 14 - COMPARISON OF CASE DISTRIBUTION BASED ON 
PREVIOUS AED INTAKE IN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
S. 
No. Previous Drug 
Fosphenytoin 
Group 
(n=25) 
Levetiracetam 
Group 
(n=25) 
Total 
1 Sodium valproate 4 5 9 
2 Phenobarbitone 6 2 8 
3 No drug 15 18 33 
 TOTAL 25 25 50 
 
               Data is expressed in percentage. ‘p’ value less than 0.05 is 
considered as significant and Fisher’s Exact test was used to test the 
significance. 
 
                   Out of 50 children, 17 of them had previous anti-epileptic drug 
intake. 10 of them received Fosphenytoin and the remaining 7 children were 
treated with Levetiracetam (p=0.762 , not significant). 
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FIGURE 10 - COMPARISON OF CASE DISTRIBUTION BASED ON 
PREVIOUS AED INTAKE IN FOSPHENYTOIN AND LEVETIRACETAM 
GROUP 
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7) COMPARISON OF TYPE OF SEIZURES IN BOTH GROUPS: 
 
TABLE 15 - COMPARISON OF CASE DISTRIBUTION BASED ON 
THE TYPE OF SEIZURE IN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
 
S. 
No. 
Parameter 
(type of 
seizure) 
Group I 
(Fosphenytoin) 
(n=25) 
Group II 
(Levetiracetam) 
(n=25) 
‘P’ 
Value 
Statistical 
Test 
1 Focal 4%(1) 4%(1) 
0.999 
(NS) 
Fisher’s 
Exact test 
2 Generalised 96%(24) 96%(24) 
 
                      Data is expressed in percentage. ‘p’ value less than 0.05 is 
considered as significant and Fisher’s Exact test was used to test the 
significance. 
Among the 50 children, only 2 children had focal seizures and 
remaining 48 children had generalized tonic clonic seizures which was not 
statistically significant (‘p’=1.000). 
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FIGURE 11– COMPARISON OF CASE DISTRIBUTION BASED ON THE 
TYPE OF SEIZURE IN FOSPHENYTOIN AND LEVETIRACETAM 
GROUP 
 
 
*Data are expressed as absolute numbers. 
*The Length of the bar in the vertical bar diagram represents 
number of subjects (n). 
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8) COMPARISON OF DURATION OF SEIZURES IN BOTH 
GROUPS: 
TABLE 16 - COMPARISON OF CASE DISTRIBUTION BASED ON THE 
DURATION OF SEIZURE IN FOSPHENYTOIN AND LEVETIRACETAM 
GROUP 
 
S. 
No. Parameter 
Group I 
(Fosphenytoin) 
Group II 
(Levetiracetam) 
‘P’ 
Value 
Statistical 
TesT 
1 
Duration of 
seizure 
(in minutes) 
21.48 ±  4.28 22.12 ± 4.97 
0.628 
(NS) 
Unpaired ‘t’ 
test 
 
Data is expressed as Mean ± SD. ‘p’ value less than 0.05 is considered 
as significant and Mann Whitney U test was used to test the significance. 
 
The mean duration of seizure activity in fosphenytoin group was             
21.48 ± 4.28 minutes  whereas in levetiracetam group it was 22.12 ± 4.97 
minutes which was not statistically significant (‘p’=0.628) 
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FIGURE 12 COMPARISON OF CASE DISTRIBUTION BASED ON THE 
DURATION OF SEIZURE IN FOSPHENYTOIN AND LEVETIRACETAM 
GROUP 
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FIGURE 13 COMPARISON OF ALL BASELINE CHARACTERISTICS 
BETWEEN BOTH STUDY GROUPS: 
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TABLE 17 - BASELINE CHARACTERISTICS AND THEIR ‘P’ VALUE 
S. 
N
o. 
Parameter 
FPHT 
Group 
(n=25) 
LEV 
Group 
(n=25) 
‘P’ 
Value Inference 
1 AGE (mean ± SD) in years 3.34 ± 3.6 
2.28 ± 
2.19 
0.657 Not 
significant 
2. GENDER 
Male 16(64%) 18(72%) 
0.762 Not 
significant Female 9(36%) 7(28%) 
3. WEIGHT (in kg) 
11.86 ± 
8.9 
10.42 ± 
5.9 
0.95 Not 
significant 
4 PREVIOUS SEIZURE 
DISORDER 
Yes 9(36%) 7(28%) 
0.762 Not 
significant No 16(64%) 18(72%) 
5 
TYPE OF 
SEIZURE 
Focal 1(4%) 1(4%) 
0.999 Not 
significant GTCS 24(96%) 24(96%) 
6. DEVELOPMENT 
 Abnormal 8(32%) 7(28%) 
0.999 Not 
significant Normal 17(68%) 18(72%) 
7. 
DURATION OF SEIZURES 
(minutes) 
21.48 ± 
4.28 
22.12 ± 
4.97 
0.628 Not 
significant 
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TABLE 18 - ETIOLOGICAL PROFILE OF THIS STUDY POPULATION 
S.n
o 
ETIOLOGY FPHT (n=25) LEV (n=25) 
1   Cryptogenic 7(28%) 5(20%) 
2  Acute CNS infection 4(16%) 6(24%) 
3  Febrile seizures 4(16%) 4(16%) 
4   HIE Sequelae 3(12%) 4(16%) 
5 Seizure disorder (non-compliance) 3(12%) 1(4%) 
6 Syndromic association 1(4%) 1(4%) 
7 Hypoglycemia 1(4%) 1(4%) 
8 Thulasi oil intoxication 1(4%) 0(0%) 
9 Seizure disorder (Breakthrough disorder ) 0(0%) 1(4%) 
10 Sepsis 1(4%) 0(0%) 
11 Camphor intoxication 0(0%) 1(4%) 
12 Post meningo-encephalitic 
sequelae 0(0%) 1(4%) 
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 FIGURE 14 – ETIOLOGICAL PROFILE OF FOSPHENYTOIN GROUP 
 
 
FIGURE 15 – ETIOLOGICAL PROFILE OF LEVETIRACETAM GROUP 
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STATISTICAL ANALYSIS OF THE OUTCOME OF THE STUDY: 
PRIMARY OUTCOME: 
A. TERMINATION OF SEIZURE ACTIVITY AFTER DRUG 
ADMINSTRATION  
 
TABLE 19-COMPARISON OF SEIZURE CESSATION RATE 
FOLLOWING DRUG ADMINISTRATION IN FPHT AND LEV 
GROUP 
 
S. 
No. 
Parameter 
(Termination 
of seizure) 
Group I 
(Fosphenytoin) 
(n=25) 
Group II 
(Levetiracetam) 
(n=25) 
‘P’ 
Value 
Statistical 
Test 
1 Yes 84% (21) 92%(23) 0.6671 
(NS) 
Fisher’s 
Exact test 2 No 16%(4) 8%(2) 
 
In our study, seizure cessation rate following fosphenytoin 
administration was 84% whereas for levetiracetam it was 92%. 
However ‘p’ value was found to be insignificant. 
The percentage of children requiring additional anti-epileptic drugs to 
terminate the presenting convulsions was 16% and 8% for fosphenytoin 
and levetiracetam group respectively.  
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FIGURE 16-COMPARISON OF SEIZURE CESSATION RATE 
FOLLOWING DRUG  ADMINISTRATION IN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
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B. TIME TAKEN TO TERMINATE SEIZURES: 
TABLE 20– COMPARISON OF TIME TAKEN TO TERMINATE 
SEIZURES FOLLOWING DRUG ADMINISTRATION IN FPHT 
AND LEV GROUP 
S. 
NO. Parameter 
Fosphenytoin 
Group 
Levetiracetam 
Group 
‘P’ 
Value 
 
Statistical 
Test 
1 Time needed to terminate 
seizure 
2.5 ± 1.4 min 3.3 ± 1.16 min 0.029* Unpaired 
‘t’ test 
 
   In our study the mean time taken to terminate seizures was 2.5 ± 1.4 minutes 
in Fosphenytoin group. For Levetiracetam it was about 3.3 ± 1.16 minutes.  
 The ‘P’ value was found to be statistically significant (0.029) 
FIGURE 17-COMPARISON OF TIME TAKEN TO TERMINATE 
SEIZURES FOLLOWING DRUG ADMINISTRATION IN 
FOSPHENYTOIN AND LEVETIRACETAM GROUP 
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SECONDARY OUTCOMES: 
C.RECURRENCE OF SEIZURE: 
 
TABLE 21-COMPARISON OF RECURRENCE OF SEIZURE IN 
FPHT AND LEV GROUP 
S. 
No. 
Parameter 
(Recurrence) 
Fosphenytoin 
Group 
(n=21) 
Levetiracetam 
Group 
(n=23) 
‘P’ 
Value 
Statistical 
Test 
1 Yes 9.5%(2) 17.5%(4) 
0.44 
Fisher’s 
Exact 
Test 
2 No        90.5%(19)           82.5%(19) 
3 Total              21               23 
 
 
 In our study, Fosphenytoin group had a recurrence of 9.5% whereas 
levetiracetam group had 17.5% recurrence. The ‘P’ value was found to be 
insignificant. Hence both fosphenytoin and levetiracetam had no significant 
variations in causing breakthrough seizures. 
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FIGURE 18-COMPARISON OF RECURRENCE OF SEIZURE IN 
FPHT   AND LEV GROUP. 
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 D.SEIZURE FREE INTERVAL: 
TABLE 22 - COMPARISON OF SEIZURE FREE DURATION 
FOLLOWING DRUG ADMINISTRATION IN FPHT AND LEV 
GROUP WHEN SEIZURE RECURS 
S. 
No. Parameter 
Fosphenytoin 
Group(n=2) 
Levetiracetam 
Group(n=4) 
‘P’ 
Value 
Statistical 
test 
1. Seizure free interval 
(hours) 
1.6±1.1 
 
3.8±6.3 
 
0.8 
Mann 
Whitney U 
test 
 
In our study, there was no significant variation in seizure free duration 
following drug administration between both groups 
 
FIGURE 19 - COMPARISON OF SEIZURE FREE DURATION 
FOLLOWING DRUG ADMINISTRATION IN FPHT AND LEV GROUP 
WHEN SEIZURE RECURS 
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E.IMPACT ON HOSPITAL STAY: 
       TABLE 23- COMPARISON OF LENGTH OF PICU AND HOSPITAL 
STAY IN FPHT AND LEV GROUP 
 
S. 
No. 
 
Duration of 
stay 
 
Fosphenytoin 
Group 
 
Levetiracetam 
Group 
 
‘P’ 
Value 
 
Statistical 
test 
1 PICU(hours) 42.3 ± 65.1 44 ± 26.7 0.105 
Mann 
Whitney U 
test 
2 Hospital(days) 5.8 ± 4.9 6.3± 3.7 0.311 
 
     There was no difference in the length of PICU (42.3 hours vs. 44 
hours) and hospital stay between two groups. The mean duration of hospital 
stay for Fosphenytoin group was 6.41 days and for Levetiracetam group was 
6.06 days. 
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FIGURE 20- COMPARISON OF LENGTH OF PICU STAY IN FPHT AND 
LEV GROUP 
 
 
FIGURE 21- COMPARISON OF LENGTH OF HOSPITAL STAY IN  
                     FPHT AND LEV GROUP 
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FIGURE 22- COMPARISON OF ‘P’ VALUES OF BOTH PRIMARY AND 
SECONDARY OUTCOMES BETWEEN FOSPHENYTOIN AND 
LEVETIRACETAM GROUP 
 
 
*Statistically significant. 
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E. NEED FOR VENTILATORY ASSISTANCE AND LIFE 
THREATENING HYPOTENSION: 
TABLE 24 – COMPARISON OF LIFE THREATENING ADVERSE DRUG 
REACTIONS IN FPHT AND LEV GROUP 
S.no Adverse event 
observed 
FPHT  
Group 
LEV  
Group  
1 Hypotension treated 
with inotropes 
 
1(4%) 
 
1(4%) 
 
These adverse effects 
were documented in 
children who needed 
additional AEDs to 
terminate the presenting 
seizures.  2 
 
Respiratory 
depression 
(ventilator 
assistance) 
 
4(16%) 
 
1(4%) 
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F.ADVERSE EFFECTS:  
TABLE 25 – COMPARISON OF SPECIFIC ADVERSE DRUG 
REACTIONS IN FPHT AND LEV GROUP WHO DID NOT REQUIRE 
ADDITIONAL AEDS 
S. 
No. 
ADVERSE EFFECT FOSPHENYTOIN LEVETIRACETAM 
1 
Respiratory depression 
(non-intubated) 
1(4%) 0(0%) 
2 Ataxia 1(4%) 0(0%) 
3 
Behavioral changes 
(irritable cry & 
somnolence) 
0(0%) 1(4%) 
4 Thrombocytopenia 0(0%) 1(4%) 
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TABLE 26 - DEPICTS THE COMPARISON OF EFFICACY OF BOTH 
DRUGS 
S. 
No. Parameter 
Fospheytoin 
Group 
Levetiracetam 
Group 
‘P’ 
Value Inference 
1 
Seizure 
termination 
rate 
84% 92% 0.6671 Not 
significant 
1. 
Time taken to 
terminate 
seizures 
(minutes) 
2.5±1.4 3.3 ± 1.16 0.029* Significant 
2. Recurrence 
of seizures 9.5% 17.5% 0.44 
Not 
significant 
3. 
Seizure free 
interval 
(hours) 
1.6 ±  1.1 3.8 ± 6.3 0.8 Not 
significant 
4. PICU stay (hours) 42.3± 65.1 44 ± 26.7 0.105 
Not 
Significant 
5. Hospital stay (days) 5.8 ± 4.9 6.3± 3.7 0.311 
Not 
significant 
6. Adverse 
events 8% 8% - - 
 
In our study Fosphenytoin terminated seizures in 84% of the children 
whereas levetiracetam’s seizure cessation rate was 92%. Fosphenytoin 
terminated seizure earlier than Levetiracetam (2.5 minutes vs. 3.3 minutes; P= 
0.029*).  
Comparison of efficacy of Fosphenytoin and Levetiracetam in different 
domains including recurrence of seizures, seizure free duration and hospital 
stay were not statistically significant.  
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On comparing the secondary outcome following treatment with either 
fosphenytoin or levetiracetam; 2 cases had adverse drug reactions in each 
group. One child had respiratory depression requiring nasal oxygen and other 
developed transient ataxia following fosphenytoin infusion.  In levetiracetam 
group behavioral changes and thrombocytopenia were the adverse events 
noted. 
Case fatality rate was 8% in our study. All the children required 
additional AED & the cause of death was mutifactorial 
 
TABLE 27 – MORTALITY AND ITS ASSOCIATIONS IN THIS STUDY 
S.no PREDICTORS NUMBER OF CASES (n=4) 
  FPHT LEV TOTAL (n=4) 
1 Age less than 1 year 3 1 4 
2 Need of additional AEDs to terminate seizures 3 1 4 
3 
Acute symptomatic etiology 2 1 3 
Remote  symptomatic etiology 1 0 1 
4 
Focal seizures 0 1 1 
 Generalize Tonic clonic 
seizures 3 0 3 
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DISCUSSION 
 
The study was done during a period of 6 months from January -June 
2017. There were a total of 68 children who presented with status epilepticus 
during this time period of which, 50 children fulfilled the inclusion criteria. 
Among those 50 children, 25 of them were treated with Fosphenytoin and the 
remaining with Levetiracetam. 
In this study, we compared fosphenytoin with levetiracetam in terms of 
their effectiveness (both efficacy and adverse drug reactions) in 
benzodiazepine resistant status epilepticus. 
          In the study Group I (Fosphenytoin group), 64% were male children. 
The mean age was 3.34 years; with a mean weight of 11.86 kg and mean 
seizure duration of 21.48 minutes. Previous AED intake was found in 10 cases 
and delayed developmental milestones in 32%. 
        In the study Group II (Levetiracetam group), 72% were male children. 
The mean age was 2.28 years; with a mean weight of 10.42 kg and mean 
seizure duration of 22.12 minutes. Previous AED intake was found in 7 cases 
and delayed developmental milestones in 28%. 
 The most common type of seizure was GTCS followed by focal 
seizures in 8%. None had myoclonic seizures. 
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            The etiology of seizures in the study group with decreasing order of 
frequency based on clinical findings were acute symptomatic (acute CNS 
infection, hypoglycemia and intoxication), remote symptomatic , cryptogenic 
status epilepticus and febrile status epilepticus. 
In our study, seizure cessation rate following fosphenytoin 
administration was 84% whereas for levetiracetam it was 92%. In a previous 
study done by Zeid Yasiry et al, the efficacy of levetiracetam was 68.5% and 
phenytoin was 50.2%. [32] In their study, 798 cases of convulsive SE were 
analyzed retrospectively.  The study by Alvarez et al throws a contrary picture 
with seizure cessation rate of 58.2% and 51.7% for phenytoin and 
levetiracetam respectively, which was statistically insignificant as in our 
study. [27] There is no previous data comparing fosphenytoin with 
levetiracetam in children. 
 
TABLE 28 - COMPARISON OF VARIOUS STUDIES WITH REGARDING 
TO SEIZURE CESSATION RATE 
S. 
No. Study 
Phenytoin 
/Fosphenytoin Levetiracetam ‘P’ Value 
1 Our study 84% (fosphenytoin) 92% 
Not 
significant 
2 Zeid Yasiry et al 50.2% (phenytoin) 68.5% - 
3 Alvarez et al 58.2% (phenytoin) 51.7% 
       Not 
significant 
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In our study fosphenytoin terminated seizures earlier than levetiracetam. 
The mean time taken to terminate seizures was 2.5 ± 1.4 minutes in 
fosphenytoin group. For levetiracetam it was about 3.3 ± 1.16 minutes.  
According to Jaclyn O’Connor and her associates, time needed to terminate 
seizures was similar (P= 0.085) in both study groups. [3] However their study 
was done on adults. 
In the fosphenytoin group, 9.5% (2/21) had recurrence, whereas the 
levetiracetam group had 17.5% (4/23) recurrence which is similar to the 
results of a study in adults done by Chakravarthy et al. [28] It is not 
comparable to the study done by Jacyln O’ Connor and her colleagues, where 
breakthrough seizures occurred less in LEV group (22%vs.38% p=0.014*.)[3] 
In our study, there was no significant variation in seizure free duration 
following drug administration between both groups. None of the studies 
compared this parameter. 
There was no difference between the two groups in length of PICU 
(42.3 vs. 44; p= 0.105) and hospital Stay (5.8 days hrs vs. 6.3 days; p= 0.311).  
This was similar to the study conducted by Jaclyn O’ Connor et al between 
these two drugs on adults. [3] 
 In a systematic review by Egunsola O et al on the safety of 
levetiracetam in pediatric population, it was found that behavioral problems 
and somnolence to be the most prevalent adverse event to levetiracetam. [21] 
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In our study, behavioral changes were observed in 4% of cases in the form of 
irritable cry. 
          According to Kinshuk Sahaya, out of 755 patients, 29 patients were 
recognized with fall in platelet count while on levetiracetam prophylaxis. [34] 
In our study, only one child (4%) was documented to have thrombocytopenia. 
The cause of thrombocytopenia is uncertain in view of associated sepsis in that 
child. 
In a study by Jamerson et al, 8 out of 12 patients treated with phenytoin 
experienced phlebitis but was noted on only one case with fosphenytoin (P < 
0.05)[35]. In our study, no case of phlebitis was documented. 
According to Leppik and his colleagues, serious cardiovascular and 
respiratory adverse reactions were not observed during IV infusion of FPHT 
[33]. In our study, hypotension was noted in two cases (1 each from FPHT & 
LEV group), but they also needed additional AEDs (like phenobarbital or 
midazolam) to terminate the seizures.  
In Ramsay RE and Wilder BJ et al study,   67% of patient receiving 
parenteral phenytoin experienced transient CNS side effects like nystagmus, 
ataxia and dizziness but no patient developed intolerance to fosphenytoin. [36] 
In our study, ataxia was noted in 1 child (4%) treated with fosphenytoin, who 
recovered on switching to oral anti-epileptic drugs. 
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LIMITATIONS OF THIS STUDY 
 
• The sample size of the study was small. 
• The primary outcome does not include electroencephalography 
confirmation of seizure termination. 
• The cause of death was multifactorial. 
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SUMMARY 
50 children aged between 1 month and 12 years presenting to pediatric 
emergency department at Govt. Rajah Mirasdar hospital, Thanjavur from 
January 2017 to June 2017 with status epilepticus that has failed to terminate 
with two doses of midazolam were included in this study. Children in shock, 
who were on oral phenytoin and levetiracetam medications and who were 
treated with injectable antiepileptic drugs in previous 24 hours were excluded 
from this study.  
Participants were administered 30 mg PE/kg of intravenous fosphenytoin 
over 10 min & 30 mg/kg of intravenous levetiracetam over 6 min. The primary 
outcome of the study is the clinical cessation of seizure activity and the need 
for additional AED to terminate seizures. Secondary outcomes includes a) 
recurrence, b) serious adverse events & c) length of PICU and hospital stay. 
Fosphenytoin achieved control of SE in 89% patients compared to 
levetiracetam in 82% (p=0.6671). Fosphenytoin terminated seizure earlier than 
Levetiracetam (2.54mins vs. 3.3 mins; P=0.029). There was no significant 
difference between the two groups with respect to recurrence of seizures 
within 24 hours (p=0.44), seizure free duration when seizure recurs (p=0.8) 
and duration of PICU and hospital stay (p=0.105 & 0.311) .The adverse events 
did not differ significantly between two groups. 
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CONCLUSION 
 
 Fosphenytoin terminated seizures earlier than levetiracetam. 
Levetiracetam may be an effective alternative to fosphenytoin in management 
of SE in children in view of comparable efficacy in terms of termination of 
seizures, recurrence of seizures, adverse events & length of hospital stay. 
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ANNEXURE 2 
PROFORMA 
NAME -                          AGE -                  SEX- 
IP NO – 
SOCIOECONOMIC  STATUS: (modified Kuppusamy scale) 
PRESENTING ILLNESS: 
Seizure (duration, type, features) 
H/O fever 
H/O trauma 
Other relevant history 
PAST ILLNESS: 
Whether a known case of seizure disorder or not? 
Any AED intake – 
TREATMENT HISTORY: 
For the presenting complaints, whether the child had been treated outside with 
any forms of injectable drugs. 
FAMILY HISTORY: 
Pedigree & Consanguinity:  
ANTENATAL/ NATAL/POSTNATAL HISTORY: 
(Relevant details) 
 
 
89 
 
IMMUNIZATION HISTORY: 
DEVELOPMENTAL HISTORY  
Gross motor/ 
Fine motor Cognition Social 
Activities of 
daily living 
    
 
Delay in developmental 
milestones  
No delay in developmental 
milestones  
 
WEIGHT FOR AGE 
Normal >80%  
Grade I malnutrition 70 – 80%  
Grade II malnutrition 60 – 70%  
Grade III malnutrition 50 - 60%  
Grade IV malnutrition < 50%  
 
2.HEIGHT  
90 %   
90 -95%   
85 -90%   
< 85%   
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   3. HEAD CIRCUMFERENCE 
-3SD TO 
 -2SD 
-2 SD  
TO  
-1 SD 
-1SD 
TO  
MEDIAN 
MEDIAN 
TO  
+1 SD 
+ 1 SD 
TO 
+2 SD 
+ 2 SD  
TO 
+3 SD 
      
 
GENERAL EXAMINATION: 
Look for dysmorphism&Look for neurocutaneous marker 
VITALS:  1.HEART RATE: 
Bradycardia  
Normal  
Tachycardia  
  (Using age specific Heart rate data)  
2.RESPIRATORY RATE: 
Bradypnoea  
Normal   
Tachypnoea  
(Using age specific respiratory rate data)  
3. BLOOD PRESSURE: (Expressed  in centile) 
Less than 5th centile  
Normal   
More than 95th centile  
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4.CAPILLARY REFILL TIME: 
Normal  
Prolonged   
 
 5.PERIPHERAL PULSES: 
Not felt  
Well felt  
 
6.TEMPERATURE: 
Febrile  
Afebrile  
 
SYSTEMIC EXAMINATION:  
CNS  
HIGHER MENTAL FUNCTION: 
 CRANIAL NERVES: 
 MOTOR:   - Co-ordination    
         -BULK                  - TONE  - POWER  - REFLEXES 
PLANTAR REFLEX:         
INVOLUNTARY MOVEMENTS:  
    SENSORY: 
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CEREBELLAR 
S/O MENINGEAL IRRITATION: 
CVS 
RS 
ABDOMEN  
DATA ANALYSIS 
 FOSPHENYTOIN LEVETIRACETAM 
AVAILABILITY   
COST 
  
 
 
FOSPHENYTOIN LEVETIRACETAM 
 
PREVIOUSLY 
NEUROLOGIC
ALLY  
NORMAL 
PREVIOUSLY 
NEUROLOGIC
ALLY  
ABNORMAL 
PREVIOUSLY 
NEUROLOGIC
ALLY  
NORMAL 
PREVIOUSLY 
NEUROLOGIC
ALLY  
ABNORMAL 
ANY PRE-
HOSPITAL 
TREATMENT 
    
WHETHER 
STATUS 
TERMINATED 
    
TOTAL 
DURATION 
NEEDED TO 
CONTROL 
STATUS (from 
drug 
administered to 
seizure activity 
termination) 
    
RECURRENCE 
WITHIN 24 hrs 
    
SEIZURE 
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FREE 
INTERVAL 
AFTER 
INITIAL DOSE 
(in case of 
recurrence) 
NEED OF 
ADDITIONAL 
AED 
    
 
CESSATION OF STATUS : 
 It is the termination of all seizure activity within 30 minutes following drug 
administration. 
ABSENCE OF RECURRENCE : 
It is absence of recurrence of seizure within 24 hours  
 FOSPHENYTOIN LEVETIRACETAM 
INCIDENCE OF ADR   
DURATION OF PICU 
STAY 
  
IMPACT IN HOSPITAL 
STAY 
  
FOSPHENYTOIN  % observed LEVETIRACETAM % observed 
Respiratory depression  Somnolence 
 
Hypotension  Behaviour changes 
 
Cardiac arrythmias  ANY OTHERS 
 
Extravastion of drug when 
administered through IV 
  
 
Did side effects warrant 
discontinuation of therapy? 
  
 
ANY OTHERS    
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INVESTIGATIONS: 
CBC  
RBS 
SERUM ELECTROLYTES 
SERUM CALCIUM 
LFT 
DIAGNOSIS: 
Seizure type → 
Etiology → 
Syndromic association → 
Etiology  IV 
Fosphenytoin 
IV Levetiracetam 
Non – compliance   
Acute CNS infection   
Febrile status   
Metabolic cause   
Miscellaneous    
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ANNXEURE 3 
CONSENT FORM 
 
       I                                                                   hereby give consent for my 
child to  participate in the study conducted by Dr.KOWSIK.M, post graduate 
in Department of Pediatrics , Thanjavur Medical College , Thanjavur – 
613001 and to  use my child’s personal clinical data and result of investigation 
for the purpose of analysis and to study the nature of disease. 
 
Name of the participant- 
Place – 
Signature of Parent – 
Date- 
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ANNEXURE 4 
ABBREVIATIONS USED: 
 
 AED – Anti-Epileptic Drug 
 BP – Blood Pressure 
 BZD – Benzodiazepines 
 CNS – Central Nervous System 
 HIE – Hypoxic Ischemic Encephalopathy  
 PICU – Pediatric Intensive Care Unit 
 LEV – Levetiracetam 
 FPHT – Fosphenytoin 
 SE– Status Epilepticus 
 ILAE- International League Against Epilepsy 
 PE- Phenytoin Equivalent 
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ANNEXURE 5 
MASTER CHART 
KEY TO MASTER CHART 
      
S.No          PARAMETER  
 
 
Previous seizure 
disorder 
 
Y – Yes 
N – No 
2 Previous AED PBT – Phenobarbitone 
SVP – Sodium valproate 
3 Etiology SEP  -     Sepsis 
SD    -      New onset seizure disorder 
HIE   -     Hypoxic Ischemic Encephalopathy 
FSE   -    Febrile Status Epilepticus 
MEN     Meningitis 
SDNC – Seizure Disorder Non  
                   Compliance of AED 
ACI  -     Acute CNS infection 
SDBS  -  Seizure Disorder  
               Breakthrough Seizures 
SYN –    Syndromic Association 
HYPO -  Hypoglycemia 
 
4 Type of seizures F – Focal 
G – Generalized tonic clonic 
5 Developmental 
History 
AB – Abnormal 
N – Normal 
6 ADR(Adverse drug 
reactions) 
HT –          Hypotension 
RD –          Respiratory depression 
ATA –        Ataxia 
BC(IC) –    Behavioral changes (Irritable cry) 
THROM – Thrombocytopenia 
DEA -        Death 
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FP
S.No Name Age ( years) Yr to mth conv Age (month) Total in month age yr final
weight in 
Kg
prev sez 
disorder (Y/N)
AE drug 
taken
etiology
type of 
seizure
duration 
of seizure 
(min)
develop
mental 
history
time 
drug adm 
to sz 
cessa
whether 
seizure 
terminat
ed or not
recurrenc
e
seizure 
free 
interval 
(hrs)
need of 
additiona
l drug to 
terminat
e present 
seizures
additiona
l AED to 
terminat
e present 
seizure
PICU stay 
in hr
total 
hospital 
stay 
(days)
ADR 
documented 
1
ADR 
documen
ted 2
ADR 
documen
ted 3
ADR 
documen
ted 4
1 JAGADHEEP 0 0 6 6 0.5 4.5 Y PBT SEP F 26 AB 0 N Y PBT 288 17 HT(IN) RD(I)
2 KOWSALYA 9 108 108 9 18 N SD G 18 N 3 Y NR N 3
3 MOHAMMED AMEERA 0 11 11 0.916666667 8 Y PBT HIE G 31 N 1.5 Y NR N 3
4 KATHIR 3 36 4 40 3.333333333 12 N FSE G 28 N 2 Y NR N 8 7
5 VIBIN 0 8 8 0.666666667 5 N SVP HIE G 17 AB 0 N Y PBT+MID 84 3 RD(I) DEA
6 MEGHA 0 0 5 5 0.416666667 3.4 Y PBT MEN G 20 AB 0 N Y PBT+MID 18 0.75 RD(I) DEA
7 SATHRIYAN 0 6 6 0.5 5 N FSE G 21 N 3.5 Y NR N 5
8 HEMA SHREE 0 11 11 0.916666667 7 N SD G 16 N 3 Y NR N 24 3
9 SAI PRADAP 3 36 6 42 3.5 10 N SD G 22 N 2 Y NR N 3
10 NITHISH 3 36 36 3 11 N SD G 18 N 4 Y NR N 3.25
11 CHANDRU 3 36 36 3 12 N SD G 15 N 3.5 Y NR N 4 3
12 EZHILRANI 4 48 48 4 15 Y SVP SDNC G 23 AB 2 Y NR N 48 5
13 KAVISH RAJA 7 84 84 7 20 Y PBT SD G 26 N 1.5 Y NR N 20 3
14 THILSATH BEEVI 11 132 132 11 25 N SD G 15 N 2.5 Y NR N 7 3
15 VISHWA 3 36 36 3 10.2 N FSE G 24 N 3 Y NR N 24 4
16 KAVYA 1 12 1 13 1.083333333 7 N SYN G 18 AB 3 Y NR N 16 7
17 ANANYA 0 5 5 0.416666667 5 N ACI G 26 N 4 Y NR N 32 14
18 SHANKAR 11 132 132 11 31 Y SVP SDNC G 22 AB 3.5 Y R 2H 28M N 24 2
19 LITHESH 0 4 4 0.333333333 3 Y PBT ACI G 24 AB 0 N Y PBT+MID 23 1 RD(I) DEA
20 THILLAI RAJAN 1 12 12 1 8.5 N ACI G 18 N 3 y R 50M N 10 14 RD(NI)
21 THARIKA 0 0 1 1 0.083333333 3.3 N HG G 26 N 2.5 Y NR N 51 14
22 DINESH 1 12 6 18 1.5 7.5 Y PBT HIE G 22 AB 2 y NR N 3
23 YAMUNA 5 60 7 67 5.583333333 18.5 N FSE G 24 N 4 Y NR N 12 7
24 KARTHIKEYAN 1 12 3 15 1.25 8.5 N THULASI OIL G 18 N 5 Y NR N 104 16 ATA
25 SADASIVAMN 11 132 132 11 38 Y SVP SDNC G 19 N 4 Y NR N 7 2
LC LEVETIRACETAM
S.No Name Age ( years) Yr to mth conv Age (month) Total in month age yr final
weight in 
Kg
prev sez 
disorder (Y/N)
AE drug 
taken
etiology
type of 
seizure
duration 
of seizure 
(min)
develop
mental 
history
time 
drug adm 
to sz 
cessa
whether 
seizure 
terminat
ed or not
recurrenc
e
seizure 
free 
interval 
(hrs)
need of 
additiona
l AED to 
control 
present 
seizure
additiona
l AED to 
terminat
e initial 
seizure
PICU stay 
in hr
total 
hospital 
stay 
(days)
ADR 
documented 
1
ADR 
documen
ted 2
ADR 
documen
ted 3
ADR 
documen
ted 4
1 RAMKUMAR 3 36 36 3 12.5 Y SVP PMS G 28 AB 4 Y NR N 25 4.5
2 JITHESH 2 24 6 30 2.5 11 N FSE G 16 N 3.5 Y R 13 H 22M N 72 10
3 ABISHEK 0 11 11 0.916666667 7 N SD G 17 N 4 Y NR N 3 BC(IC)
4 SIVAPRIYA 0 8 8 0.666666667 5.8 N ACI G 15 N 4.5 Y NR N 70 10
5 VINITH 1 12 6 18 1.5 9 N CRS G 26 AB 4 Y NR N 24 5
6 SAIKARTHIKEYAN 1 12 3 15 1.25 8 Y SVP HIE G 23 AB 3 Y NR N 3
7 MAHESH 1 12 1 13 1.083333333 10 N SD G 21 N 2.5 Y NR N 3
8 PREETHI 4 48 48 4 15 N ACI G 24 N 0 N Y PBT 98 14 RD(NI)
9 DHIVAN 2 24 24 2 11 N SD G 18 N 3.5 Y NR N 22 11
10 HARISH 0 7 7 0.583333333 5 N SD G 31 N 4 Y NR N 4
11 LOGANAYAKI 4 48 6 54 4.5 15 Y SVP SDNC G 28 AB 4.5 Y R 25 M N 48 7
12 HARISH 0 6 6 0.5 4.5 N HIE G 24 AB 3.5 Y NR N 4
13 KAVINESH 1 12 4 16 1.333333333 7.5 N FSE G 18 N 4 Y NR N 5
14 FAZIL 8 96 96 8 21 Y SVP SDBS G 17 N 3 Y NR N 2
15 KANISH 0 4 4 0.333333333 4 N ACI G 22 N 4 Y NR N 12 13 THROM
16 JEEVANSHREE 1 12 12 1 7 N CAMPHOR G 29 N 2 Y NR N 1
17 ROSHAN 1 12 6 18 1.5 10 N ACI G 20 N 3 Y NR N 28 10
18 YOGESHWARI 3 36 3 39 3.25 12 N SD G 16 N 4 Y NR N 3
19 MUTHUMANI 0 4 4 0.333333333 5 Y PBT HIE G 18 AB 4 Y R 1 H 30 M N 44 5
20 HARIVARSAN 6 72 6 78 6.5 30 N FSE G 31 N 4 Y NR N 10
21 SASIDHARAN 0 5 5 0.416666667 4.8 Y PBT HIE G 19 AB 3.5 Y NR N 5
22 ABDUL FAIZ 0 11 11 0.916666667 9 N ACI F 25 N 0 N Y PBT+MID 72 3 RD(I) HI(INO) DEA
23 ANBUSELVI 0 10 10 0.833333333 6.5 N FSE G 24 N 3 y NR N 15 10
24 EBSHIBA 7 84 84 7 18 Y SVP HYPO G 26 N 4 Y NR N 3
25 YAZHINI 3 36 3 39 3.25 12 N ACI G 17 N 3.5 Y R 18 M N 42 10
 
